2.1
Obinutuzumab (Gazyvaro, Roche), in combination with mycophenolate mofetil (MMF) is indicated for 'the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN)'.
2 Information about obinutuzumab with mycophenolate mofetil
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for obinutuzumab.
Price
2.3
The list price is £3,312.00 per 1,000‑mg vial (excluding VAT, BNF online, accessed December 2025).
2.4
The company has a commercial arrangement. This makes obinutuzumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Roche's website (PDF only).